Bevan Marshall

Bevan Marshall

Auto-generated profile, based on publicly available information

Bevan Marshall

Biomedical Manufacturing, CSIRO Parkville, 343 Royal Parade, Parkville Vic 3052, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2015 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
BMB Marshall
B Marshall
HPH Puthalakath
H Puthalakath
SCS Caria
S Caria
SCS Chugh
S Chugh
MDM Doerflinger
M Doerflinger
Marc KvansakulMarc Kvansakul
Marc Kvansakul
Subversion of host cell apoptosis is an important survival strategy for viruses to ensure their own proliferation and survival. Certain viruses express proteins homologous in sequence, structure and function to mammalian pro-survival B-cell lymphoma 2 (Bcl-2) proteins, which prevent rapid clearance of infected host cells. In vaccinia virus (VV), the virulence factor F1L was shown to be a potent inhibitor of apoptosis that functions primarily be engaging pro-apoptotic Bim. Variola virus (VAR), the causative agent of smallpox, harbors a homolog of F1L of unknown function. We show that VAR F1L is a potent inhibitor of apoptosis, and unlike all other characterized anti-apoptotic Bcl-2 family members lacks affinity for the Bim Bcl-2 homology 3 (BH3) domain. Instead, VAR F1L engages Bid BH3 as well as Bak and Bax BH3 domains. Unlike its VV homolog, variola F1L only protects against Bax-mediated apoptosis in cellular assays. Crystal structures of variola F1L bound to Bid and Bak BH3 domains reveal that variola F1L forms a domain-swapped Bcl-2 fold, which accommodates Bid and Bak BH3 in the canonical Bcl-2-binding groove, in a manner similar to VV F1L. Despite the observed conservation of structure and sequence, variola F1L inhibits apoptosis using a startlingly different mechanism compared with its VV counterpart. Our results suggest that unlike during VV infection, Bim neutralization may not be required during VAR infection. As molecular determinants for the human-specific tropism of VAR remain essentially unknown, identification of a different mechanism of action and utilization of host factors used by a VAR virulence factor compared with its VV homolog suggest that studying VAR directly may be essential to understand its unique tropism.

28 July 2015 in Acta Crystallographica Section D Structural Biology
Verified
Journal Article
Closed access
DBDenis R. Burton
Denis R. Burton
SCSofia Caria
Sofia Caria
BMBevan Marshall
Bevan Marshall
MBMichele Barry
Michele Barry
Marc KvansakulMarc Kvansakul
Marc Kvansakul

1 July 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SCSofia Caria
Sofia Caria
BMBevan Marshall
Bevan Marshall
RBRobyn-Lee Burton
Robyn-Lee Burton
SCStephanie Campbell
Stephanie Campbell
DPDelara Pantaki-Eimany
Delara Pantaki-Eimany
Marc KvansakulMarc Kvansakul
Marc Kvansakul
Subversion of host cell apoptotic responses is a prominent feature of viral immune evasion strategies to prevent premature clearance of infected cells. Numerous poxviruses encode structural and functional homologs of the Bcl-2 family of proteins, and vaccinia virus harbors antiapoptotic F1L that potently inhibits the mitochondrial apoptotic checkpoint. Recently F1L has been assigned a caspase-9 inhibitory function attributed to an N-terminal α helical region of F1L spanning residues 1–15 (1) preceding the domain-swapped Bcl-2-like domains. Using a reconstituted caspase inhibition assay in yeast we found that unlike AcP35, a well characterized caspase-9 inhibitor from the insect virus Autographa californica multiple nucleopolyhedrovirus, F1L does not prevent caspase-9-mediated yeast cell death. Furthermore, we found that deletion of the F1L N-terminal region does not impede F1L antiapoptotic activity in the context of a viral infection. Solution analysis of the F1L N-terminal regions using small angle x-ray scattering indicates that the region of F1L spanning residues 1–50 located N-terminally from the Bcl-2 fold is an intrinsically unstructured region. We conclude that the N terminus of F1L is not involved in apoptosis inhibition and may act as a regulatory element in other signaling pathways in a manner reminiscent of other unstructured regulatory elements commonly found in mammalian prosurvival Bcl-2 members including Bcl-xL and Mcl-1.

30 June 2013 in Acta Crystallographica Section F Structural Biology and Crystallization Communications
Verified
Journal Article
Open access
PDF file
JNJanet Newman
Janet Newman
DBDenis R. Burton
Denis R. Burton
SCSofia Caria
Sofia Caria
SDSebastien Desbois
Sebastien Desbois
CGChristine L. Gee
Christine L. Gee
TPThomas Peat
Thomas Peat
Crystallization of macromolecules is famously difficult. By knowing what has worked for others, researchers can ease the process, both in the case where the protein has already been crystallized and in the situation where more general guidelines are needed. The 264 crystallization communications published in Acta Crystallographica Section F in 2012 have been reviewed, and from this analysis some information about trends in crystallization has been gleaned. More importantly, it was found that there are several ways in which the utility of these communications could be increased: to make each individual paper a more complete crystallization record; and to provide a means for taking a snapshot of what the current `best practices' are in the field.

26 June 2018 in Acta Crystallographica Section F Structural Biology Communications
Verified
Journal Article
Closed access
PDF file
NRNicholas Rosa
Nicholas Rosa
MRMarko Ristic
Marko Ristic
BMBevan Marshall
Bevan Marshall
JNJanet Newman
Janet Newman

7 February 2020 in Crystals
Verified
Journal Article
Open access
PDF file
NRNicholas Rosa
Nicholas Rosa
MRMarko Ristic
Marko Ristic
LTLuke Thorburn
Luke Thorburn
GAGabriel J. Abrahams
Gabriel J. Abrahams
BMBevan Marshall
Bevan Marshall
JNJanet Newman
Janet Newman
The process of macromolecular crystallisation almost always begins by setting up crystallisation trials using commercial or other premade screens, followed by cycles of optimisation where the crystallisation cocktails are focused towards a particular small region of chemical space. The screening process is relatively straightforward, but still requires an understanding of the plethora of commercially available screens. Optimisation is complicated by requiring both the design and preparation of the appropriate secondary screens. Software has been developed in the C3 lab to aid the process of choosing initial screens, to analyse the results of the initial trials, and to design and describe how to prepare optimisation screens.